TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is a Healthcare company (Medical - Devices) with a market capitalization of $142M. The Maz Rating grades it against the other companies in its sector.
TriSalus Life Sciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.29, TriSalus Life Sciences, Inc. trades at 3.0x sales and 194.8x book value. Over the last twelve months it generated about $47M of revenue and a net loss of $31M. It runs a gross margin of 86.5%, an operating margin of -63.0% and a net margin of -56.6%. It shows return on equity of 759.7%, return on invested capital of -65.2% and a free cash flow yield of -22.1%. On the balance sheet: a debt-to-equity ratio of 49.55 and a current ratio of 4.22. Over the past 52 weeks the share price ranged from $2.17 to $7.95, with a beta of 0.51.
TriSalus Life Sciences, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, TriSalus Life Sciences, Inc. (TLSI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 13.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 16.7% / 30% · Interest income / Revenue 2.97% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 13.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.7% / 33% · Receivables / Mkt Cap (36m) 2.49% / 49% · Interest income / Revenue 2.97% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 13.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.7% / 33.33% · Receivables / Mkt Cap (24m) 2.49% / 33.33% · Interest income / Revenue 2.97% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 59.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 72.6% / 33.33% · Receivables / Avg Assets (4Q) 10.8% / 33.33% · Interest income / Revenue 2.97% / 5% | Fail |
| FTSE | Debt / Total Assets 56.2% / 33.33% · (Cash+ST Inv) / Total Assets 71.3% / 33.33% · (Cash+Recv) / Total Assets 82.0% / 33.33% · Interest income / Revenue 2.97% / 5% | Fail |
It depends on the standard you follow. As of September 2026, TriSalus Life Sciences, Inc. (TLSI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. TriSalus Life Sciences, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.97% of each dividend: TriSalus Life Sciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.